Fig. 5
From: Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Neutralization of SARS-CoV-2 variants by therapeutic mAbs. The neutralization abilities of therapeutic mAbs against wild-type, D614G and newly emerged SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.427 and B.1.429 (Epsilon), B.1.526 (Iota), B.1.617.1 (Kappa), and B.1.617.2 (Delta). Symbols and colors indicate the range of half maximal inhibitory concentration (IC50) values toward authentic SARS-CoV-2 virus. +++ with blue, IC50 < 10 ng/ml; ++ with light blue, IC50 = 10–100 ng/ml; + with white, IC50 = 100–1000 ng/ml; —, IC50 with red > 1000 ng/ml; ND with grey, no determined; #, preliminary results reported on the website of Celltrion Healthcare Co., Ltd.; *, the range of IC50 values toward pseudotype SARS-CoV-2 virus. RBD, receptor-binding domain; RBM, receptor-binding motif. The mutant amino acids in RBD of each SARS-CoV-2 spike protein are shown as indicated